Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

‘A new alternative’: Tiny pacemakers for infants show early promise
A team of pediatric specialists worked closely with representative from Medtronic to develop the new pacemakers. Overall, the tiny devices—approximately one-quarter the size of a traditional pacemaker—were found to be both safe and effective. They are still under development.
Cardiologists make history, complete world’s first robotic transcatheter mitral valve replacements
One of the cardiologists involved in the procedures said they represent "a significant leap forward in structural heart intervention."
FDA approves design updates for Perceval Plus surgical aortic valve
The valve's sutureless, collapsible frame was built to simplify implantation and help patients recover faster following surgery. This updated version features laser-cut details and was shaped using a zero-pressure fixation process.
Cardiologists are first in world to use new TAVR catheter from Boston Scientific
The new Self-Centering Guide Catheter was designed to help care teams with the retrograde crossing of the aortic valve during TAVR. Researchers evaluated the safety and effectiveness of the catheter, sharing their experience in JACC: Cardiovascular Interventions.
TAVR vs. SAVR: Real-world data highlight advantages of both techniques
The biggest differences, researchers noted, were found in the long-term outcomes of low- and intermediate-risk patients.

Paul Sorajja, MD, director, Center for Valve and Structural Heart Disease, Minneapolis Heart Institute, Abbott Northwestern Hospital, was the principal investigator for the late-breaking TRILUMINATE pivotal trial at the American College of Cardiology (ACC) 2023 meeting and explains details of this landmark trial. #ACC #ACC23 #triluminate

TRILUMINATE trial may pave the way for FDA clearance for tricuspid valve clip device

Paul Sorajja, MD, discusses the late-breaking TRILUMINATE pivotal trial at ACC.23 and how tricuspid TEER performed against the current standard of care using medical therapy.

Links to all the American College of Cardiology late-breaking studies for ACC.23

Here are links to more information on every late-breaking presentation at ACC.23.

ACC 2023 program chair Douglas Drachman, MD, explains the top takeaways from the American College of Cardiology meeting. #ACC #ACC23

Key takeaways from the ACC 2023 annual meeting

ACC.23 Program Chair Doug Drachman, MD, explains what he saw as some of the key takeaways from the American College of Cardiology (ACC) 2023 annual meeting.

What new data tell us about TAVR in women with a history of early menopause

Researchers examined data from more than 700 TAVR patients, publishing their findings in the American Journal of Cardiology.

New American College of Cardiology President B. Hadley Wilson shares his goals for the future

The veteran interventional cardiologist told Cardiovascular Business he sees potential in the ACC's ability to grow both nationally and internationally in the next year.

ACC 2023 ACC.23 American College of Cardiology

Day 2 at ACC.23 features late-breaking studies on TEER, TAVR, EHR alerts and much more

Catch up on the biggest news that came out of the second day of ACC.23 in New Orleans.

ACC.23 Together with the World Congress of Cardiology

Day 1 at ACC.23 features late-breaking studies on bempedoic acid, tricuspid valve repair and statins

The conference kicked off with three late-breaking studies that could have a huge impact on patient care going forward.

A transcatheter aortic valve replacement (TAVR) procedure being performed at Intermountain Healthcare. Image from Intermountain Healthcare

10 reasons heart teams may consider SAVR over TAVR when treating aortic stenosis

As much as TAVR's popularity has grown in recent years, there are still many instances when a heart team may find that surgery offers the best path forward.

Structural Heart Disease

‘A new alternative’: Tiny pacemakers for infants show early promise

Cardiologists make history, complete world’s first robotic transcatheter mitral valve replacements

FDA approves design updates for Perceval Plus surgical aortic valve

Cardiologists are first in world to use new TAVR catheter from Boston Scientific

TAVR vs. SAVR: Real-world data highlight advantages of both techniques